Johnson Financial Group Inc. Decreases Holdings in Pfizer Inc. $PFE

Johnson Financial Group Inc. reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 114,948 shares of the biopharmaceutical company’s stock after selling 23,366 shares during the quarter. Johnson Financial Group Inc.’s holdings in Pfizer were worth $3,228,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vermillion Wealth Management Inc. boosted its holdings in Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 382 shares in the last quarter. Triad Wealth Partners LLC increased its stake in Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares during the last quarter. Eagle Capital Management LLC raised its holdings in Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares in the last quarter. ETF Store Inc. lifted its position in shares of Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 396 shares during the last quarter. Finally, Delta Financial Advisors LLC boosted its holdings in shares of Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after buying an additional 398 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer faces expanded international patent lawsuits over its COVID-19 vaccine, with Arbutus Biopharma and Genevant Sciences seeking damages and possible injunctions. That raises legal and operational uncertainty for the company. Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
• Negative Sentiment: Pfizer was noted as falling more than the broader market in the latest session, reinforcing near-term weakness in the stock. Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
• Negative Sentiment: Erste Group Bank lowered earnings estimates for Pfizer, which can signal softer expectations for future profitability. Erste Group Bank Decreases Earnings Estimates for Pfizer
• Neutral Sentiment: Pfizer has been drawing heavy user interest on Zacks, but the coverage is largely a stock-screening/discussion piece rather than a new company-specific catalyst. Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
• Neutral Sentiment: Separate articles highlighted Pfizer as a possible contender in the $100 billion weight-loss market and as a cheap income stock, which supports the bullish long-term narrative but does not change near-term fundamentals on its own. Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? Looking for Cheap Income Stocks? Why Pfizer Belongs on Your Shortlist Right Now

Pfizer Price Performance

Shares of PFE opened at $24.75 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The firm has a 50-day simple moving average of $25.19 and a 200-day simple moving average of $26.18. The company has a market capitalization of $141.04 billion, a price-to-earnings ratio of 18.89 and a beta of 0.35.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s payout ratio is presently 131.30%.

Analyst Ratings Changes

A number of research firms recently commented on PFE. UBS Group reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. CICC Research assumed coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. BMO Capital Markets cut their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Finally, Citigroup boosted their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.50.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.